CTLA4 and cancer: Particularly in immunologically deserted tumors, this approach could also prove synergistic with immune checkpoint inhibitors such as anti-PD-1 or anti-CTLA-4 antibodies, which have been shown to be effective in certain cancers in combination with RT.